NADK is a human gene whose product NADK encodes NAD kinase, the enzyme that catalyzes NADP+ biosynthesis from NAD+. It is the first and rate-limiting step in NADP+ production. NADK variants have been implicated in Alzheimer's Disease and Parkinson's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Full NameNAD Kinase
SymbolNADK
Chromosomal Location1p36.23
NCBI Gene ID[55712](https://www.ncbi.nlm.nih.gov/gene/55712)
OMIM[607785](https://www.omim.org/entry/607785)
Ensembl IDENSG00000008130
UniProt ID[Q9P2R7](https://www.uniprot.org/uniprot/Q9P2R7)
Associated Diseases[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)
NADK encodes NAD kinase, the enzyme that catalyzes NADP+ biosynthesis from NAD+. It is the first and rate-limiting step in NADP+ production 1. This enzyme plays a critical role in maintaining cellular redox balance and supporting biosynthetic pathways essential for neuronal survival and function.
NADK catalyzes the phosphorylation of NAD+ to produce NADP+:
NAD+ + ATP → NADP+ + ADP
This reaction requires magnesium ion (Mg2+) as a cofactor and represents the sole known enzymatic pathway for de novo NADP+ synthesis in mammalian cells. The enzyme exhibits Michaelis-Menten kinetics with a Km for NAD+ of approximately 0.1-0.5 mM and a Vmax that varies with tissue type and metabolic state [1].
NADK is essential for maintaining NADP+ levels, which serve multiple critical cellular functions [1][4]:
NADPH Production:
- Antioxidant defense: NADPH provides reducing equivalents for glutathione reductase and NADPH oxidase
- Biosynthetic reactions: Fatty acid synthesis, cholesterol synthesis, and nucleotide synthesis require NADPH
- DNA repair: PARP activity consumes NAD+, and NADPH supports repair processes
- Immune response: NADPH oxidase in phagocytic cells generates reactive oxygen species for microbial killing
Redox Balance:
The NADP+/NADPH ratio is tightly regulated in cells, typically maintained at approximately 1:10. This ratio is crucial for:
- Counteracting oxidative stress in neurons, which are particularly vulnerable to reactive oxygen species due to high metabolic demand
- Maintaining the reduced glutathione pool essential for detoxification
- Supporting mitochondrial function and ATP production
NADK is crucial for neuronal health through multiple mechanisms [2][3][5][6]:
Alzheimer's Disease:
NADK activity declines in AD brains, reducing NADPH and increasing oxidative stress 2. Research has demonstrated:
- Reduced NADK protein expression and activity in prefrontal cortex and hippocampus of AD patients [7]
- Decreased NADP+/NADPH ratio correlates with disease severity
- NADK reduction contributes to impaired antioxidant defense and increased amyloid-beta toxicity [16]
- Tau pathology may directly or indirectly affect NADK function [17]
Parkinson's Disease:
NADK protects dopaminergic neurons from oxidative stress and mitochondrial toxins 3[8]:
- 6-OHDA and MPTP toxicity is attenuated by NADK overexpression
- NADK maintains glutathione levels essential for dopaminergic neuron survival
- Mitochondrial complex I inhibition in PD may involve NADK dysregulation
- α-Synuclein aggregation affects NADK activity
Aging:
NADK expression decreases with age, contributing to NADP+ depletion 4[18]:
- Age-related decline in NADK contributes to metabolic inflexibility
- Reduced NADP+ impairs stress response mechanisms
- Caloric restriction partially reverses age-related NADK decline
NADK dysfunction contributes to AD through multiple interconnected pathways [2][7][16][17]:
Mechanisms:
- Reduced NADPH → impaired antioxidant defense
- Increased oxidative stress and lipid peroxidation
- Impaired DNA repair via PARP inhibition
- Mitochondrial dysfunction and energy deficit
- Accelerated amyloid-beta aggregation
- Tau hyperphosphorylation and neurofibrillary tangle formation
Therapeutic Implications:
- NADK activators may restore NADP+ levels in AD brain
- Combined NAD+ and NADK boosting strategies being explored
- Gene therapy approaches to increase NADK expression
In PD, NADK provides neuroprotection through several mechanisms [3][8][9]:
Dopaminergic Neuron Protection:
- Protection against 6-OHDA and MPTP toxicity
- Maintenance of glutathione levels
- Support of mitochondrial function and ATP production
- Preservation of dopaminergic neuron-specific signaling
Mitochondrial Quality Control:
- NADK supports mitophagy through NADP+-dependent pathways
- Protects against mitochondrial DNA damage
- Maintains mitochondrial membrane potential
Therapeutic Strategies:
- Small molecule NADK activators in development [19]
- AAV-mediated NADK gene delivery being investigated
- Combination approaches with NAD+ precursors
Amyotrophic Lateral Sclerosis (ALS):
- NADK activity reduced in motor neurons of ALS patients
- SOD1 mutant toxicity exacerbated by NADK deficiency
- Therapeutic targeting under investigation
Diabetic Neuropathy:
NADK dysregulation contributes to diabetic nerve damage [20]:
- Hyperglycemia-induced NADK impairment
- Oxidative stress accumulation
- Polyol pathway hyperactivity
Huntington's Disease:
- NADK supports neuronal energy homeostasis
- Mutant huntingtin affects NADK function
- NADP+ supplementation may be beneficial
NADK is ubiquitously expressed with highest levels in tissues with high metabolic activity [1]:
| Tissue |
Expression Level |
| Brain |
High (cortex, hippocampus) |
| Liver |
Very High |
| Heart |
High |
| Skeletal muscle |
High |
| Kidney |
Moderate |
| Lung |
Moderate |
| Pancreas |
Moderate |
Within the brain, NADK shows region-specific expression [5]:
- Cortex: Highest in pyramidal neurons of layers 2-6
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Substantia nigra: Dopaminergic neurons
- Cerebellum: Purkinje cells
- Brainstem: Motor and sensory nuclei
NADK localizes primarily to the cytosol, with some association with:
- Mitochondrial outer membrane
- Nuclear envelope
- Endoplasmic reticulum
Cytosolic localization supports both general cellular functions and neuron-specific requirements. The mitochondrial association is particularly important for neuronal energy metabolism.
NADK expression is developmentally regulated:
- Low expression during embryonic development
- Increases postnatally with neuronal maturation
- Highest expression in adult brain
- Declines with age in multiple brain regions
NADK activity is regulated at multiple levels:
Transcriptional Regulation:
- p53 directly activates NADK transcription
- c-Myc promotes NADK expression
- SIRT1 deacetylase modulates NADK gene expression
- Circadian clock genes regulate NADK rhythms
Post-Translational Regulation:
- Phosphorylation by PKC and PKA
- Acetylation by p300/CBP
- Ubiquitination and proteasomal degradation
- Sumoylation under stress conditions
Allosteric Regulation:
- ATP concentration affects activity
- NAD+ and NADP+ feedback inhibition
- Magnesium ion requirement
NADK integrates with multiple signaling pathways:
Calcineurin-NFAT → NADK transcription
↓
AMPK → NADK activation (energy sensing)
↓
p53 → NADK activation (stress response)
↓
SIRT1 → NADK regulation (metabolism)
Key Interactions:
- AMPK activation increases NADK activity
- p53 tumor suppressor activates NADK
- SIRT1 deacetylates and activates NADK
- mTORC1 represses NADK expression
Modulating NADK activity represents a promising therapeutic strategy [6][10][19][21]:
Activation Strategies:
- Small molecule activators: Compounds that directly activate NADK [19]
- Indirect activation: NAD+ precursors that increase substrate availability
- Gene therapy: AAV-mediated NADK overexpression [10]
- Protein engineering: Engineered NADK variants with enhanced activity
Combination Approaches:
- NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) with NADK activators
- Antioxidant therapy combined with NADK boosting
- Mitochondrial protectants with NADK modulators
- Blood-brain barrier penetration of small molecules
- Tissue-specific delivery
- Dose optimization
- Long-term safety concerns
- Patient stratification based on NADK activity
NADK expression and activity may serve as biomarkers [15][18]:
- NADK levels in cerebrospinal fluid
- NADP+/NADPH ratio as metabolic marker
- Genetic variants affecting treatment response
- Expression changes correlating with disease progression
NADK knockout mice have been generated and exhibit:
- Embryonic lethality: Complete knockout is embryonic lethal
- Conditional knockouts: Tissue-specific deletion reveals essential functions
- Brain-specific knockout: Severe neurodegeneration phenotype
- Mitochondrial dysfunction: Impaired oxidative phosphorylation
NADK overexpression studies demonstrate:
- Neuroprotection: Resistance to various toxic insults
- Enhanced antioxidant capacity: Improved glutathione maintenance
- Improved mitochondrial function: Better energy metabolism
- Extended neuronal survival: In various disease models
In various neurodegenerative disease models:
- AD models: Reduced amyloid-beta and tau pathology with NADK overexpression
- PD models: Protected dopaminergic neurons
- ALS models: Improved motor neuron survival
- Aging models: Reduced age-related cognitive decline
| Partner |
Interaction Type |
Functional Consequence |
| p53 |
Transcriptional activation |
Cell cycle and stress response |
| AMPK |
Phosphorylation |
Energy sensing |
| SIRT1 |
Deacetylation |
Metabolic regulation |
| PKC |
Phosphorylation |
Signal transduction |
| Mitochondrial proteins |
Physical association |
Energy metabolism |
NADK interacts with cellular networks:
- Metabolic pathways: Central carbon metabolism
- Antioxidant systems: Glutathione and thioredoxin
- DNA repair: PARP and SIRT1 pathways
- Mitochondrial function: TCA cycle and ETC
¶ Protein Domains
NADK contains several functional domains:
- NAD-binding domain: Binds NAD+ substrate at the N-terminus
- ATP-binding domain: Recognizes and binds ATP phosphate groups
- Catalytic core: Contains the active site for phosphate transfer
- Regulatory domain: Contains sites for allosteric regulation
Crystal structures have revealed:
- Open and closed conformations
- Substrate-induced conformational changes
- Dimer interface formation
- Allosteric binding sites
NADK is evolutionarily conserved:
- Bacteria: Primarily NAD-dependent
- Yeast: Both NAD and NADP kinases
- Mammals: Dedicated NADK enzyme
- Plants: Multiple NADK isoforms
Across species:
- Catalytic mechanism is conserved
- Regulation differs by organism
- Subcellular localization varies
- Tissue distribution patterns differ
NADK as a biomarker:
- CSF NADK activity measurement
- Peripheral blood monocyte assessment
- Imaging-based detection approaches
- Genetic screening for variants
Current pharmaceutical efforts:
- High-throughput screening for activators
- Structure-based drug design
- Prodrug approaches for brain delivery
- Gene therapy vector development
Several classes of NADK activators are under development:
Direct Activators:
- Bind to allosteric sites on NADK
- Increase Vmax without affecting Km
- Subtype selectivity being optimized
Indirect Activators:
- Increase NAD+ availability
- NAMPT activators to boost NMN
- NAD+ precursors combined with NADK activation
Blood-Brain Barrier (BBB):
- Molecular weight <400 Da preferred
- Lipophilicity for membrane passage
- Active transport systems being explored
Target Engagement:
- Measuring NADK activity in brain tissue
- PET tracers for NADK visualization
- Pharmacodynamic biomarkers
Patient Selection:
- Biomarker stratification
- Genotype-based enrollment
- Disease stage optimization
Endpoints:
- NADP+/NADPH ratio in CSF
- Cognitive measures
- Imaging biomarkers
- Safety monitoring
Key experimental techniques:
- Enzyme activity assays
- NADP+/NADPH quantification
- Subcellular fractionation
- Protein interaction studies
Research tools:
- CRISPR knockout and knockin
- siRNA and shRNA knockdown
- Transgenic and knockout mice
- Patient-derived iPSCs
flowchart TD
A["NAD+<br/> substrate"] -->|"NADK catalysis"| B["NADP+<br/> product"]
B -->|"reducing power"| C["Antioxidant Defense<br/>Glutathione, Thioredoxin"]
B -->|"biosynthesis"| D["Fatty Acid<br/>Cholesterol Synthesis"]
B -->|"DNA repair"| E["PARP Activity<br/>DNA Repair"]
B -->|"mitochondrial"| F["Mitochondrial Function<br/>ETC, TCA Cycle"]
C --> G["Neuroprotection"]
D --> G
E --> G
F --> G
style A fill:#e1f5fe,stroke:#333
style B fill:#e1f5fe,stroke:#333
style G fill:#c8e6c9,stroke:#333
Several NADK variants have been associated with disease risk [9]:
- Missense variants: Altered enzymatic activity
- Regulatory variants: Changed expression levels
- Splice variants: Altered isoforms
- Increased risk of late-onset AD
- Modifier of PD progression
- Variant modifying age of onset
- Structure-function studies: Understanding NADK catalytic mechanism
- Therapeutic development: Small molecule NADK activators
- Biomarker development: NADK as disease biomarker
- Gene therapy: Viral delivery approaches
- Combination therapies: NADK modulators with other treatments
- Personalized medicine approaches based on NADK genotype
- Prevention strategies targeting NADK in at-risk individuals
- Biomarker development for patient selection
- Novel delivery systems for CNS targeting
Recent metabolomics approaches have revealed:
- NADP+ and NADPH levels as key metabolic indicators
- Correlation with disease severity in AD and PD
- Potential for diagnostic use
Computational approaches to NADK targeting:
- Network-based target identification
- Polypharmacology for combination therapy
- Patient-specific metabolic modeling
From bench to bedside:
- Preclinical validation of lead compounds
- IND-enabling studies
- Early-phase clinical trials
NADK (NAD Kinase) is a critical enzyme that catalyzes the rate-limiting step in NADP+ biosynthesis. Located at 1p36.23, this gene encodes a protein essential for maintaining cellular redox balance, supporting antioxidant defenses, and enabling biosynthetic pathways crucial for neuronal survival [1][6].
In neurodegeneration, NADK dysfunction plays a significant role:
- Alzheimer's Disease: NADK activity decline contributes to oxidative stress, impaired antioxidant defense, and accelerated pathology [2][7][16]
- Parkinson's Disease: NADK protects dopaminergic neurons from oxidative damage and mitochondrial toxins [3][8]
- Aging: NADK expression decreases with age, contributing to metabolic decline [4][18]
The enzyme represents a promising therapeutic target, with multiple approaches under investigation including small molecule activators, gene therapy, and combination strategies [6][10][19][21]. Understanding NADK biology continues to reveal new opportunities for treating currently intractable neurodegenerative conditions.
- NADK catalyzes the sole de novo pathway for NADP+ synthesis
- NADP+ is essential for antioxidant defense, biosynthesis, and DNA repair
- NADK activity declines in AD and PD brains
- NADK provides neuroprotection through multiple mechanisms
- Therapeutic targeting of NADK is an active area of research
- Animal models demonstrate neuroprotective potential of NADK activation
- Combination approaches with NAD+ precursors show promise
- Biomarker development for patient selection is ongoing